AU Patent

AU2012202711A1 — Viral polymerase inhibitors

Assigned to Boehringer Ingelheim International GmbH · Expires 2012-05-31 · 14y expired

What this patent protects

C:\NRPonbnDCCRBR\430991 I LDOC-A)5/2012 An enantiomer, diastereoisomer or tautomer of a compound, represented by formula (1): wherein either A or B is nitrogen and the other B or A is C, and the radicals R1, R2, R , R4 , R , 5 R', R', R', R9, and R10 are as defined herein, or a s…

USPTO Abstract

C:\NRPonbnDCCRBR\430991 I LDOC-A)5/2012 An enantiomer, diastereoisomer or tautomer of a compound, represented by formula (1): wherein either A or B is nitrogen and the other B or A is C, and the radicals R1, R2, R , R4 , R , 5 R', R', R', R9, and R10 are as defined herein, or a salt or ester thereof as viral polymerase inhibitors. The compound is used as an inhibitor of RNA dependent RNA polymerases, particularly those viral polymerases within the Flaviviridae family, more particularly to HCV polymerase.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012202711A1
Jurisdiction
AU
Classification
—
Expires
2012-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.